Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$135.27 - $180.11 $14.1 Million - $18.8 Million
-104,500 Reduced 19.0%
445,500 $61 Million
Q2 2022

Aug 15, 2022

BUY
$108.81 - $179.33 $49 Million - $80.7 Million
450,000 Added 450.0%
550,000 $97.3 Million
Q1 2022

May 16, 2022

SELL
$119.61 - $157.85 $70 Million - $92.3 Million
-585,000 Reduced 85.4%
100,000 $14.4 Million
Q4 2021

Feb 14, 2022

BUY
$142.57 - $190.86 $21.1 Million - $28.2 Million
148,000 Added 27.56%
685,000 $106 Million
Q3 2021

Nov 15, 2021

SELL
$142.45 - $169.82 $14.7 Million - $17.5 Million
-103,000 Reduced 16.09%
537,000 $91.2 Million
Q2 2021

Aug 16, 2021

BUY
$135.08 - $161.1 $8.39 Million - $10 Million
62,100 Added 10.75%
640,000 $101 Million
Q1 2021

May 17, 2021

BUY
$137.51 - $190.8 $79.5 Million - $110 Million
577,900 New
577,900 $80.2 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.